Add to ORKG© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. The authors grant exclusive rights to all commercial reproduction and distribution to Libertas Academica. Commercial reproduction and distribution rights are reserved by Libertas Academica. No unauthorised commercial use permitted without express consent of Libertas Academica. Contac
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
Copyright: © 2013 Robak T. This is an open-access article distributed under the terms of the Creati...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Lice...
The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenous leukemia, and immune me...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article publi...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic mye...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
Copyright: © 2013 Robak T. This is an open-access article distributed under the terms of the Creati...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Lice...
The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenous leukemia, and immune me...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article publi...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic mye...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...